Study to Measure the Efficacy and Safety of Abrocitnib Versus Placebo and Dupilumab to Treat Moderate to Severe Atopic Dermatitis in Adults Receiving Background Topical Therapy. A Phase 3 Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Center Study Investigating the Efficacy and Safety of PF-04965842 and Dupilumab in Comparison With Placebo in Adult Subjects on Background Topical Therapy, With Moderate to Severe
Atopic Dermatitis.